Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1

share with twitter share with LinkedIn share with facebook
06/30/2020 | 02:04am EDT
Designation follows recent US approval with additional regulatory submissions underway

Phase II SPRINT trial showed selumetinib reduced tumour volume in paediatric patients with NF1 plexiform neurofibromas

Disclaimer

AstraZeneca plc published this content on 30 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 June 2020 06:03:05 UTC

share with twitter share with LinkedIn share with facebook
Latest news on ASTRAZENECA PLC
12:13pUK shares surge as upbeat factory activity data lifts global sentiment; HSBC ..
RE
07:15aGilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
DJ
06:55aASTRAZENECA : Wockhardt strikes deal to supply COVID-19 vaccines to UK
RE
06:53aASTRAZENECA : India's Wockhardt strikes deal to supply COVID-19 vaccines to UK
RE
05:48aWOCKHARDT : India's Wockhardt strikes deal to supply COVID-19 vaccines to UK
RE
04:48aUK shares surge as upbeat factory activity data lifts global sentiment; HSBC ..
RE
02:56aASTRAZENECA : Top Indian ministers in hospital as virus cases breach 50,000 for ..
RE
02:06aASTRAZENECA : Goldman Sachs maintains a Sell rating
MD
07/31Large U.S. COVID-19 vaccine trials will exclude pregnant women for now
RE
07/31Sanofi, GlaxoSmithKline Ink Coronavirus Vaccine Deal With U.S. -- Update
DJ
More news
Financials (USD)
Sales 2020 26 755 M - -
Net income 2020 3 009 M - -
Net Debt 2020 13 529 M - -
P/E ratio 2020 53,9x
Yield 2020 2,45%
Capitalization 150 B 150 B -
EV / Sales 2020 6,13x
EV / Sales 2021 5,39x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 113,51 $
Last Close Price 114,65 $
Spread / Highest target 27,0%
Spread / Average Target -1,00%
Spread / Lowest Target -47,7%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC15.25%147 070
JOHNSON & JOHNSON-0.08%383 760
ROCHE HOLDING AG0.67%296 096
PFIZER, INC.-1.79%213 750
MERCK & CO., INC.-11.78%202 534
NOVARTIS AG-17.88%182 470